Is Receptor-Interacting Protein Kinase 3 a Viable Therapeutic Target for Mycobacterium tuberculosis Infection?

The dwindling list of antimicrobial agents exhibiting broad efficacy against clinical strains of Mycobacterium tuberculosis (Mtb) has forced the medical community to redefine current approaches to the treatment of tuberculosis (TB). Host receptor-interacting protein kinase 3 (RIPK3) has been flagged...

Descripción completa

Detalles Bibliográficos
Autores principales: Stutz, Michael D., Ojaimi, Samar, Ebert, Gregor, Pellegrini, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985376/
https://www.ncbi.nlm.nih.gov/pubmed/29892302
http://dx.doi.org/10.3389/fimmu.2018.01178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985376/
https://www.ncbi.nlm.nih.gov/pubmed/29892302
http://dx.doi.org/10.3389/fimmu.2018.01178

Ejemplares similares